Introduction 8 preamplified cDNA were subjected to qPCR to determine expression patterns of target 96 genes 152 forming a "comprehensive CTC panel" using TaqMan assays and the Biomark HD instrument 153 (Fluidigm). 154 Gene expression data analysis 155 Raw Ct values generated by Biomark HD (Fluidigm) were normalized to GAPDH for each 156 sample using the -ΔCt method (25, 26) . Undetected transcripts automatically generate a Ct value 157 of 999, which were changed to Ct of 40 for numerical analyses (25, 26) . Statistical analysis was 158 performed using R software (24) . Wilcoxon rank sum tests were used to calculate differential 159 expression between PV and Pe groups, or between Clusters and Single CTCs groups. Samples on January 11, 2018. © 2017 American Association for Cancer cancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on July 17, 2017; DOI: 10.1158/0008-5472. CAN-16-2072 9 DNA was extracted from fixed (samples M1, M4) and fresh (samples M2, M3) Pre-operative peripheral (Pre-op Pe) blood was collected 0-2 hours prior to surgery. During the 186 initial phases of the operation, the pulmonary vein branches draining the cancer containing lobe 187 of the lung were identified (Figure 1) . Blood was drawn from the pulmonary vein (Intra-op PV) 188 via a 25-gauge needle early in the operation, prior to significant lung or tumor manipulation.
189
Simultaneously, blood was drawn from a peripheral vein or arterial line (Intra-op Pe). Finally, a 190 post-operative peripheral (Post-op Pe) blood draw was performed within 1-3 days of surgery.
191
Follow-up blood was drawn via a peripheral vein at the time of follow-up visits. Blood 192 specimens were collected in EDTA tubes and processed on the same day for CTC analysis. 10 Whole blood samples from patients and healthy donors ( Figure S2 ) were processed using a high-194 throughput radial flow microfluidic device, the OncoBean Chip (23) at a flow rate of 5 ml/hr, 195 using different combinations of antibodies against Epithelial Cell Adhesion Molecule (EpCAM), 196 Epidermal Growth Factor Receptor (EGFR) and CD133. Figure 3A . A distribution of the clusters segregated by their size is also 230 shown in Figure 3B . With the exception of patient P9, the peripheral blood yielded small 231 clusters (<5 CTCs), while the PV had a heterogeneous size distribution of captured CTC clusters 232 in 7/13 samples (Figure 3B ). In the 36 patient samples in which clusters of CTCs were found 233 (n=19), the number of CTCs in clusters compared to the total number of CTCs present as both 234 clusters and single cells was analyzed. The PV showed a higher median percentage of clustered 235 CTCs to total CTCs when compared to pre-op Pe and intra-op Pe. The PV also showed capture 236 of bigger clusters than the two peripheral sources (p<0.05) for clusters with ≥5CTCs and for 237 clusters with ≥10CTCs, whereas no difference was observed among the peripheral sources. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on July 17, 2017; DOI: 10.1158/0008-5472. CAN-16-2072 Intriguingly, the number of clusters with >5 or >10 CTCs showed an increasing trend with the 239 disease stage, although statistical significance was not observed due to the small sample size 240 ( Figure S3 ). However, the percentage of CTCs in clusters in pre-op peripheral blood were 241 significantly associated with stage (p=0.0061 by Kruskal Wallis test). Moreover, patients with 242 CTC clusters in the Pre-op Pe blood showed a trend towards lower progression free survival 243 (PFS) than those patients without clusters (p= 0.1058 by log-rank test), indicating the potential 244 clinical relevance of CTC clusters even in early stage lung cancer (Figure 3C) . 245 Monitoring of patients with CTC clusters 246 CTC clusters have been shown to be associated with poor prognosis (20, 27) . It is also believed 247 that the cells within clusters can escape cell death (28). Considering their prognostic significance 248 and their ability to survive, we sought to monitor patients with detectable perioperative CTC Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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Author Manuscript Published OnlineFirst on July 17, 2017; DOI: 10.1158/0008-5472. CAN-16-2072 14 The fold changes are indicated in Figure S6 . The significantly differentially expressed genes with 285 a log 2 FC greater than 2 were used to analyze enriched pathways in the PV compared to Pe 286 samples. Pathway analysis (IPathwayGuide, Advaita Bio) revealed enrichment of 'p53 signaling 287 pathway' (p=0.0012) and 'cell cycle' (p=0.0016) (Table S2) Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on July 17, 2017; DOI: 10.1158/0008-5472. CAN-16-2072 pathway' (p=0.036) suggesting activation of immune mechanisms in the clusters (Figure 6B) . 308 The 'EGFR tyrosine kinase inhibitor resistance' pathway was also highly significant (p=0.02), 309 supporting the speculation that clusters are capable of contributing to drug resistance by either 310 staying dormant, or by evading immune-activated cell death (33, 34) . 'HIF-1 signaling pathway' 311 further corroborates this conjecture, since hypoxia is known to arm tumor cells with the ability to 312 resist treatment (35, 36) . The clusters were also enriched for gene ontology terms relating to cell 313 motility and locomotion, in addition to immune regulation, suggestive of their high migratory 314 and cell survival capabilities (Figure 6C) . 315 Upon further analysis, it was revealed that Ki67, a proliferation marker, was expressed in 15/24 316 (62.5%) PV samples, and 16/27 (59.2%) Pe samples ( Figure S10 ). It was also notable that Ki67 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on July 17, 2017; DOI: 10.1158/0008-5472. CAN-16-2072 16 frequently mutated genes in lung cancer. The array includes multiple assays for genes including 330 AKT1, BRAF, CTNNB1, EGFR, ERBB2, HRAS, KRAS, NRAS, PIK3CA, STK11 and TP53. Using 331 this array, mutations were detected in 5/6 samples tested involving at least one of the genes 332 CTNNB1, EGFR, KRAS, PIK3CA and TP53 (Table 1) . Interestingly, no mutations were detected 333 in sample M1-peripheral, which had 0 CTCs detected by enumeration. TP53 mutations were 334 detected in 5/6 samples, with all 3 pulmonary vein samples positive for TP53 mutations. The 335 detailed list of specific somatic mutations for each gene tested is given in Table S4 .
336

Discussion
337
The field of circulating tumor cells (CTCs) research has seen many breakthroughs, most if not 338 all, with the common overarching theme of sampling from the peripheral blood. While the 339 peripheral blood adds convenience to ease sampling constraints, analysis is hindered by issues of 340 skin cell contamination during venipuncture (37), and detection of a diluted concentration of 341 cells as the CTCs are being circulated through the entire vasculature. Despite these challenges, 342 the peripheral blood has the advantage of more closely reflecting the metastasis initiating 343 population of cells (38) since the identified cells would likely be on their passage to distant 344 tumor formation. It would however be illuminating to identify CTCs at every "checkpoint" of 345 their passage from dissemination to new tumor formation, as they can potentially indicate the 346 dynamically changing behavior of tumor cells and the heterogeneity of tumors. We thus chose to 347 study CTCs not only at different time-points, but also from different venous sources -the 348 pulmonary vein presumably reflecting the origin of these escaping cells, and the peripheral vein 349 presumably harboring cancer cells en route to distant metastasis. We have thus followed early Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on July 17, 2017; DOI: 10.1158 /0008-5472.CAN-16-2072 We demonstrate CTC capture and analysis using a high-throughput microfluidic device, the 19 resections must be combined with CTC-eliminating strategies in order for surgery to be (48) i.e. in the PV. DNA damage is one stress mechanism that may 407 activate p53 (48), and the higher expression of the DNA repair gene ERCC1 in the PV suggests 408 that the DNA repair mechanism was active in the cells released in the PV, thereby preventing 409 activation of p53.
410
Ras protein signaling, implicated in the PV and Pe CTCs, is known to influence cell growth, 411 survival and migration, in addition to malignancy of tumor cells (30). Ras protein signaling may 412 be induced by growth factors (30). Targeting the Ras signaling pathway as a cancer treatment 413 modality is now an area of frantic research, as this pathway is activated in many different 414 cancers, including those of the lung (30,31).
415
CTC clusters or microemboli have been observed rarely in breast, prostate and lung cancers 416 (27, 37, 49) . They were shown to increase metastasis in mice models of breast cancer, and also 417 have prognostic significance in predicting survival (20, 27, 50 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on July 17, 2017; DOI: 10.1158/0008-5472. CAN-16-2072 20 absence of CTC clusters. Gene expression analysis revealed higher expression of IL6 (p=0.02) 420 among the clustered CTCs compared to single CTCs. IL6 has been shown to have an activating 421 effect on genes which can promote growth and anti-apoptosis signals (51). CTC clusters have 422 also been previously shown to be negative for apoptosis (34) . Our data supports this observation 423 by the high expression of the anti-apoptotic BCL2 gene in the clusters compared to single CTCs. 424 Together, these point to the highly aggressive or tumorigenic potential of CTC clusters (51).
425
Recent studies in breast cancer have implied that metastasis is related to CTC clusters with 426 epithelial phenotype as evidenced by expression of various keratins (50, 52) . It has also been 427 demonstrated that the clusters have high expression of adhesion markers, lack of which disrupt 428 clusters and reduce their metastatic ability (27). We too observed a higher, albeit not statistically Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on July 17, 2017; DOI: 10.1158 /0008-5472.CAN-16-2072 metastatic capability as compared to single CTCs (50). Our data additionally indicates that CTC 443 clusters may have higher migratory/motile ability than single CTCs, which might be useful in 444 their metastatic route through the bloodstream. They may also be highly efficient at evading 445 immune related cell death in the circulation, as evidenced by the GO term 'platelet activation'. 446 Indeed, 'cloaking' of CTCs by platelets has been observed and suggested as a mechanism to 447 protect the cells in circulation (54). Enrichment of the IL-17 signaling pathway is also suggestive 448 of the invasiveness of the clusters, as it has been shown that IL-17 encourages metastasis and is 449 associated with poor survival (55, 56) . to absence of proliferation as indicated by Ki67 (3, 34) . This is also corroborated by the higher 456 expression of ERCC1 (treatment resistant marker (58)) in the PV clusters, and further reinforced 457 by the upregulation of 'EGFR inhibitor resistance' and 'HIF-1 signaling' pathways in the 458 clusters. Hypoxia is theorized to promote epithelial-mesenchymal transition (36) 
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Figure Legends
